ImmPACT Bio

Sumant Ramachandra, M.D., Ph.D., CEO and Board Director

Oct. 8 | 10:15am | FLW Ballroom F 

West Hills, CA

(Private)

ImmPACT Bio USA, Inc., is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies that address key biological challenges in treating cancer and autoimmune diseases. The company’s logic-gate-based CAR T-cell platforms, licensed from University of California, Los Angeles (UCLA) Technology Development Group, are specifically designed to prevent antigen escape, overcome the immunosuppressive tumor microenvironment, and deplete pathogenic B cells. The company’s technology is based on the work of pioneering scientists Yvonne Chen, Ph.D., and Antoni Ribas, M.D., Ph.D., both from UCLA.

www.immpact-bio.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions